文献速递肝病消化道肿瘤与早癌

黏着斑激酶与β-连环蛋白协同诱导肝细胞癌

Focal Adhesion Kinase and β-Catenin Cooperate to Induce Hepatocellular Carcinoma.
PubMed 文献 · Hepatology · 2019-06-22

在癌症基因组图谱肝细胞癌标本中,16.4%存在黏着斑激酶(FAK)基因扩增并伴FAK mRNA表达升高,34.8%的FAK扩增人肝细胞癌样本同时有β-连环蛋白突变。小鼠肝内单独过表达FAK或组成性激活β-连环蛋白(CAT)均不足以致瘤,而FAK与CAT共过表达足以导致肿瘤发生,且FAK激酶活性为必需;FAK过表达增强β-连环蛋白与雄激素受体(AR)启动子结合、增加AR表达,AR降解增强剂ASC-J9抑制FAK/CAT诱导的肝细胞癌形成。

要点

  • 人肝细胞癌中FAK扩增与β-连环蛋白突变常共存。
  • 小鼠肝内FAK与CAT共过表达足以致瘤,单独过表达不足以致瘤。
  • FAK激酶活性为FAK/CAT诱导肿瘤发生所必需。

核心结论

  • FAK过表达与β-连环蛋白突变在人肝细胞癌组织中常共存,二者共过表达通过增加AR表达导致小鼠肝细胞癌形成。

研究设计与样本

  • 研究分析癌症基因组图谱肝细胞癌标本中FAK基因扩增(16.4%)及FAK mRNA表达,并检测人肝细胞癌样本中FAK扩增与β-连环蛋白突变共存情况(34.8%)。
  • 在C57/BL6小鼠肝脏中分别过表达FAK alone、组成性激活β-连环蛋白(CAT)alone或FAK与CAT组合,观察肿瘤发生。
  • 进一步验证FAK激酶活性对FAK/CAT诱导肿瘤发生的作用,并行RNA测序分析FAK、CAT或FAK/CAT调控的基因/信号通路,以及ASC-J9对FAK/CAT诱导肝细胞癌形成的影响。

主要发现

  • 癌症基因组图谱肝细胞癌标本中16.4%存在FAK基因扩增,扩增导致FAK mRNA表达增加。
  • 34.8%的FAK扩增人肝细胞癌样本同时显示β-连环蛋白突变,提示FAK过表达与β-连环蛋白突变在肝细胞癌中共存。
  • 小鼠肝内单独过表达FAK或CAT均不致瘤,而FAK与CAT共过表达足以导致肿瘤发生。
  • FAK的激酶活性为FAK/CAT诱导肿瘤发生所必需。
  • FAK过表达显著增强β-连环蛋白与雄激素受体(AR)启动子的结合,导致小鼠肝脏AR表达增加;AR降解增强剂ASC-J9抑制FAK/CAT诱导的肝细胞癌形成。

临床怎么用

  • 作者认为该小鼠模型可能有助于进一步研究肝细胞癌发病机制的分子机制,并可能有助于识别治疗靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is an urgent need to understand the molecular signaling pathways that drive or mediate the development of hepatocellular carcinoma (HCC). The focal adhesion kinase (FAK) gene protein tyrosine kinase 2 is amplified in 16.4% of The Cancer Genome Atlas HCC specimens, and its amplification leads to increased FAK mRNA expression. It is not known whether the overexpression of FAK alone is sufficient to induce HCC or whether it must cooperate in some ways with other oncogenes. In this study, we found that 34.8% of human HCC samples with FAK amplification also show β-catenin mutations, suggesting a co-occurrence of FAK overexpression and β-catenin mutations in HCC. We overexpressed FAK alone, constitutively active forms of β-catenin (CAT) alone, or a combination of FAK and CAT in the livers of C57/BL6 mice. We found that overexpression of both FAK and CAT, but neither FAK nor CAT alone, in mouse livers was sufficient to lead to tumorigenesis. We further demonstrated that FAK's kinase activity is required for FAK/CAT-induced tumorigenesis. Furthermore, we performed RNA-sequencing analysis to identify the genes/signaling pathways regulated by FAK, CAT, or FAK/CAT. We found that FAK overexpression dramatically enhances binding of β-catenin to the promoter of androgen receptor (AR), which leads to increased expression of AR in mouse livers. Moreover, ASC-J9, an AR degradation enhancer, suppressed FAK/CAT-induced HCC formation. Conclusion: FAK overexpression and β-catenin mutations often co-occur in human HCC tissues. Co-overexpression of FAK and CAT leads to HCC formation in mice through increased expression of AR; this mouse model may be useful for further studies of the molecular mechanisms in the pathogenesis of HCC and could lead to the identification of therapeutic targets.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Shang N, Wang H, Bank T, et al. Focal Adhesion Kinase and β-Catenin Cooperate to Induce Hepatocellular Carcinoma. Hepatology. 2019. PMID: 31069844. doi:10.1002/hep.30707

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。